DETAILED ACTION
Claims 1-14 are pending in the instant application.
Applicant's election with traverse of Group I in the reply filed on 07/28/2026 is acknowledged. Examiner agree to rejoin groups I and II, drawn to claims 1-4. Claims 1-4 are examiner and claims 5-14 are withdrawn per 37 CFR 1.142(b).
The requirement is still deemed proper and is therefore made FINAL.
The restriction between Groups (I-II) and (III-VIII) is remained because according to MPEP §803 “For purposes of the initial requirement, a serious burden on the examiner may be prima facie shown if the examiner shows by appropriate explanation of separate classification, or separate status in the art, or a different field of search as defined in MPEP § 808.02. That prima facie showing may be rebutted by appropriate showings or evidence by the applicant.”
2. Claim Rejections - 35 USC § 102
The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:
A person shall be entitled to a patent unless –
(a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention.
(a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention.
Claims 1-4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kitagishi et al., Chemical Communications, vol. 57(2), (2021, pages 148-173. Kitagishi et al. discloses the instant detoxifying agent on pages 157, lines 25-27; page 159, figure 13; page 160, scheme 7, line 15; page 169, lines 7-11; page 170, lines 5-10. Therefore, the instant claims are anticipated by Kitagishi et al.
3. Claims 1-4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kano et al., Chemistry-An Asian Journal (2006), 1(3), 358-366. Kano et al. discloses the instant detoxifying agent on pages 359, Figure 1, page 360, scheme 1. Therefore, the instant claims are anticipated by Kano et al.
4. Claims 1-4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Watanabe et al., ACS Medicinal Chemistry Letters (2011), 2(12), 943-947. Watanabe et al. discloses the instant detoxifying agent on pages 944, figure 1. Therefore, the instant claims are anticipated by Watanabe et al.
5. Claims 1-4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Kano et al., Dalton Transactions (2012), 41(2), 453-461. Kano et al. discloses the instant detoxifying agent on page 454, fig.1, page 455, fig. 2, page 456, scheme 2. Therefore, the instant claims are anticipated by Kano et al.
6. Claims 1-4 are rejected under 35 U.S.C. 102(a)(1) and 102(a)(2) as being anticipated by Kano et al., JP 5619500. Kano et al. discloses the instant detoxifying agent on page 4, page 14. Therefore, the instant claims are anticipated by Kano et al.
7. Claims 1-4 are rejected under 35 U.S.C. 102(a)(1) as being anticipated by Watanabe et al., Angewandte Chemie, International Edition (2013), 52(27), 6894-6897. Watanabe et al. discloses the instant detoxifying agent on page 6895, schemes 1-2. Therefore, the instant claims are anticipated by Watanabe et al.
8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Niloofar Rahmani whose telephone number is
571-272-4329. The examiner can normally be reached on Monday through Friday from 8:30 am to 5:00 pm.
If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Renee Claytor, can be reached on 571-272-8394. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/NILOOFAR RAHMANI/ Primary Examiner, Art Unit 1691 08/17/2026
Prosecution Insights